Dosing & Uses
Dosage Forms & Strengths
aspirin/dipyridamole
capsule, extended release
- 25mg/200mg
Stroke
Secondary prophylaxis of transient ischemic attack (TIA) or cerebrovascular accident (CVA)
1 capsule PO q12hr
Dosing considerations
- Not interchangeable with individual components of aspirin/dipyridamole
- Intolerable headaches during initial treatment: Switch to 1 capsule PO at bedtime; patient should return to normal regimen when possible (usually 1 week)
Dosing Modifications
GFR <10 mL/min: Use not recommended
Administration
Swallow capsules whole, without chewing
Safety and efficacy not established
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Adverse Effects
>10%
Headache (10-39%)
Dyspepsia (4-18%)
Abdominal pain (4-18%)
Nausea (6-16%)
Diarrhea (13%)
1-10%
Vomiting (3-8%)
Pain (6%)
Fatigue (6%)
Arthralgia (5%)
Back pain (5%)
Hemorrhage, nonspecific (3%)
Accidental injury (3%)
Epistaxis (3%)
Amnesia (3%)
Arthritis (2%)
Melena (2%)
Asthenia (2%)
Convulsions (2%)
Neoplasm, nonspecific (2%)
Anemia (2%)
Rectal hemorrhage (2%)
Malaise (2%)
Cardiac failure (2%)
Coughing (2%)
Purpura (1%)
GI hemorrhage (1%)
Anorexia (1%)
Somnolence (1%)
Myalgia (1%)
Arthrosis (1%)
Confusion (1%)
Hemorrhoids (1%)
Syncope (1%)
Upper respiratory tract infection (1%)
Postmarketing Reports
Body as whole: Hypothermia, chest pain
Cardiovascular: Angina pectoris, tachycardia, palpitation
CNS: Cerebral edema, dizziness, cerebral hemorrhage, intracranial hemorrhage, subarachnoid hemorrhage
Fluid and electrolyte: Hyperkalemia, metabolic acidosis, respiratory alkalosis, hypokalemia
Psychiatric Disorders: Confusion, agitation
GI: Pancreatitis, Reye syndrome, hematemesis, gastritis, ulceration and perforation, hemorrhage rectum, melena, GI hemorrhage
General: Hearing loss, anorexia, migraine
Immune: Hypersensitivity, acute anaphylaxis, laryngeal edema
Hepatic: Hepatitis, hepatic failure, cholelithiasis, jaundice, hepatic function abnormal
Musculoskeletal: Rhabdomyolysis
Metabolic: Hypoglycemia, dehydration
Reproductive: Prolonged pregnancy and labor, stillbirths, lower-birth-weight infants, antepartum and postpartum bleeding
Respiratory: Tachypnea, dyspnea
Skin: Rash, alopecia, angioedema, Stevens-Johnson syndrome, skin hemorrhage (eg, bruising, ecchymosis, hematoma), pruritus, urticaria
Urogenital: Interstitial nephritis, papillary necrosis, proteinuria, renal insufficiency and failure, hematuria
Platelet, bleeding and clotting disorders: Hematoma, gingival bleeding, epistaxis, purpura, aplastic anemia, pancytopenia, thrombocytosis, allergic vasculitis, prothrombin time (PT) prolongation, disseminated intravascular coagulation (DIC), coagulopathy, thrombocytopenia
Vascular (Extracardiac) Disorders:Flushing
Warnings
Contraindications
Hypersensitivity to aspirin, dipyridamole, or NSAIDs
Syndrome of asthma, rhinitis, and nasal polyps
Children younger than 16 years with viral infections (risk of Reye syndrome)
Cautions
Discontinue if tinnitus or impaired hearing occurs
Use with caution in patients with cardiovascular or GI diseases or bleeding disorders
Risk of precipitation of chest pain in patients with underlying coronary artery disease (CAD)
Dosage in drug may not be adequate in patients with history of stroke or TIA for whom aspirin is indicated to prevent recurrent MI or angina pectoris
Preexisting hypotension may be exacerbated by peripheral vasodilation
Increased bleeding risk when drug coadministered with antiplatelet agents (eg, anagrelide), anticoagulants (eg, heparin), fibrinolytic agents, or NSAIDs (in long-term use)
When possible, surgical patients should not receive aspirin 2 weeks before undergoing a surgical procedure
Increased bleeding risk with chronic heavy alcohol use (>3 alcoholic drinks/day)
Risk of elevated liver function test values or hepatic failure with dipyridamole administration
Intake of drug within 48 hours prior to stress testing with intravenous dipyridamole or other adenosinergic agents may increase risk for cardiovascular side effects of and may impair sensitivity of test
Pregnancy & Lactation
Pregnancy
Available data from published studies and postmarketing experience with use during pregnancy have not identified clear association between drug use and major birth defects, miscarriage, or adverse maternal or fetal outcomes drug combination contains low-dose aspirin which is an NSAID
Increases risk for bleeding; maternal use of high-dose aspirin can result in excessive blood loss at delivery, prolonged gestation, prolonged labor, intracranial hemorrhage in premature infants, low birth weight, stillbirth, and neonatal death
Animal data
- In animal reproduction studies, there were adverse developmental effects with administration of aspirin in rats and rabbits at doses about 66 and 44 times, respectively, the human exposure at maximum recommended daily dose; reproduction studies with dipyridamole in mice, rabbits, and rats have revealed no evidence of harm to fetus up to doses about 25 times maximum recommended daily human dose; nonclinical data are suggestive of possible potentiation of aspirin-related fetal toxicity when combined with dipyridamole
Lactation
Based on data from a clinical lactation study in breastfeeding women taking low-dose aspirin, the metabolite salicylic acid is present in human milk in low levels; dipyridamole is also present in human milk; there is no information on the effects of drug combination components on breastfed infant or on milk production; there is insufficient information to determine effects of aspirin on breastfed infant and no information on effects of aspirin on milk production; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from therapy or from underlying maternal condition
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Aspirin: Inhibits platelet cyclooxygenase and thus inhibits generation of thromboxane A2, a powerful inducer of platelet aggregation and vasoconstriction, leading to abrogation of platelet aggregation
Dipyridamole: Inhibits uptake of adenosine into platelets, endothelial cells, and erythrocytes
Combination of aspirin and dipyridamole produces additive antiplatelet effects
Absorption
Peak plasma levels: Dipyridamole, 2 hr
Distribution
Protein bound: Dipyridamole, 99%
Vd: Dipyridamole, 92 L
Metabolism
Metabolized by liver: Dipyridamole
Elimination
Dipyridamole: Feces (95%), urine (5%)
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.